New Platform Detects MicroRNA Directly in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Oct 2015 |
Biotech and other life science researchers will benefit from the introduction of a novel microRNA (miRNA) detection platform.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
Latest BioResearch News
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
Channels
Clinical Chemistry
view channelMultiprotein Plasma Panel Identifies Remission in Vasculitis
Vasculitis causes immune-mediated inflammation of blood vessel walls and can lead to kidney and lung damage. Clinicians rely on immunosuppressive drugs, but treatment carries significant side effects and... Read more
Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
Kidney transplantation remains constrained by organ scarcity and uncertainty about the quality of deceased-donor kidneys. In the United States, more than 92,000 people are awaiting a kidney transplant,... Read moreMolecular Diagnostics
view channel
New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
Many liquid biopsy strategies for monitoring breast cancer recurrence focus on detecting genetic mutations in tumor DNA. Researchers are evaluating whether additional features of circulating cell-free... Read more
Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
Breast cancer screening continues to face challenges, including limited detection of small tumors and uneven participation, particularly among women with dense breasts. These limitations can leave diagnostic... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read morePathology
view channel
AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer
Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more







